Skip to main content
Log in

Therapie mit Wachstumshormon bei Ullrich-Turner-Syndrom

Aktuelle Empfehlungen eines Expertenworkshops

Growth hormone therapy in Ullrich-Turner syndrome (UTS)

Expert workshop consensus

  • Konsensuspapiere
  • Published:
Monatsschrift Kinderheilkunde Aims and scope Submit manuscript

Zusammenfassung

Die Behandlung kleinwüchsiger Mädchen mit Ullrich-Turner-Syndrom (UTS) mit Wachstumshormon (WH) zur Verbesserung des Längenwachstums ist in Deutschland seit 1991 zugelassen. Die bisher empfohlene Dosis liegt bei etwa 50 µg/kgKG/Tag (tägliche subkutane Injektionen). Durch den Vergleich unterschiedlicher WH-Dosen konnte in den letzten Jahren nachgewiesen werden, dass diejenigen UTS-Patientinnen eine bessere Größenzunahme aufwiesen, die mit einer höheren als der bisher üblichen GH-Dosis behandelt worden waren. Daher hat die Europäische Zulassungsbehörde EMEA vor kurzem auf Antrag der Firma Novo Nordisk für die Behandlung der Betroffenen eine WH-Dosis von 46–67 µg/kgKG/Tag zugelassen. Der vorliegende Bericht fasst die Ergebnisse eines Workshops von Pädiatrischen Endokrinologen zusammen, welcher zum aktuellen Stand der WH-Therapie bei UTS unter Berücksichtigung dieser neuen Option abgehalten wurde. Im Rahmen des Workshops wurden verschiedene Aspekte zur WH-Therapie diskutiert wie aktueller Stand der Therapie, Hintergrund für die Dosiserhöhung, Erhöhung der Dosis generell oder nur in besonderen Situationen, mögliche Risiken, Dosisanpassung, Vorgehen in der Pubertät, Beendigung der Therapie und Transition in die Erwachsenenmedizin.

Abstract

Therapy with recombinant human growth hormone (GH) of short-statured girls with Ullrich Turner syndrome (UTS) has been authorized in Germany since 1991. To date, the daily recommended GH dose has been 50 µg/kg (s.c. injection). By comparing different GH doses, it could be shown in recent years that height gain was much better in those girls who were treated with a higher GH dose than girls treated with the recommended dose. Therefore, upon request of the company Novo Nordisk, the European Medicines Agency (EMEA) recently authorized a GH dose of 46–67 µg/kg/day for the treatment of this patient population. The current report summarizes the results of an expert workshop of pediatric endocrinologists, which was held to review the present position of GH therapy in girls with Turner syndrome in light of the higher GH dose. The workshop addressed issues such as the current status of therapy, the background to the dose increase, whether the dose should be increased in general or only in certain cases, possible risks, dosage adjustments, approaches in puberty, as well as ending therapy and transition to adult medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bakker B, Frane J, Anhalt H et al (2008) Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J Clin Endocrinol Metab 93:352–357

    Article  CAS  PubMed  Google Scholar 

  2. Bannink EM, Raat H, Mulder PG, Muinck Keizer-Schrama SM de (2006) Quality of life after growth hormone therapy and induced puberty in women with Turner syndrome. J Pediatr 148:95–101

    Article  CAS  PubMed  Google Scholar 

  3. Bannink EM, Sassen C van, Buuren S van et al (2009) Puberty induction in Turner syndrome: results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels. Clin Endocrinol (Oxf) 70:265–273

    Google Scholar 

  4. Baxter L, Bryant J, Cave CB, Milne R (2007) Recombinant growth hormone for children and adolescents with Turner syndrome. Cochrane Database Syst Rev 1:CD003887

    PubMed  Google Scholar 

  5. Binder G, Trebar B, Baur F et al (2007) Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome. Clin Endocrinol (Oxf) 68(4):567–572

    Google Scholar 

  6. Birgit B, Julius H, Carsten R et al (2009) Fertility preservation in girls with Turner syndrome: prognostic signs of the presence of ovarian follicles. J Clin Endocrinol Metab 94:74–80

    Article  CAS  PubMed  Google Scholar 

  7. Bolar K, Hoffman AR, Maneatis T, Lippe B (2008) Long-term safety of recombinant human growth hormone in Turner syndrome. J Clin Endocrinol Metab 93:344–351

    Article  CAS  PubMed  Google Scholar 

  8. Bondy CA (2007) Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 92:10–25

    Article  CAS  PubMed  Google Scholar 

  9. Canadian Growth Hormone Advisory Committee (2005) Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab 90:3360–3366

    Article  Google Scholar 

  10. Carel JC (2005) Growth hormone in Turner syndrome: twenty years after, what can we tell our patients? J Clin Endocrinol Metab 90:3793–3794

    Article  CAS  PubMed  Google Scholar 

  11. Carel JC, Ecosse E, Bastie-Sigeac I et al (2005) Quality of life determinants in young women with Turner’s syndrome after growth hormone treatment: results of the StaTur population-based cohort study. J Clin Endocrinol Metab 90:1992–1997

    Article  CAS  PubMed  Google Scholar 

  12. Chernausek SD, Attie KM, Cara JF et al (2000) Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on final height. Genentech, Inc., Collaborative Study Group. J Clin Endocrinol Metab 85:2439–2445

    Article  CAS  PubMed  Google Scholar 

  13. Davenport ML, Crowe BJ, Travers SH et al (2007) Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multi-center trial. J Clin Endocrinol Metab 92:3406–3416

    Article  CAS  PubMed  Google Scholar 

  14. Gault EJ, Paterson WF, Young D, Donaldson MD (2003) Improved final height in Turner’s syndrome following growth-promoting treatment at a single centre. Acta Paediatr 92:1033–1038

    Article  CAS  PubMed  Google Scholar 

  15. Hochberg Z, Zadik Z (1999) Final height in young women with Turner syndrome after GH therapy: an open controlled study. Eur J Endocrinol 141:218–224

    Article  CAS  PubMed  Google Scholar 

  16. Lyon AJ, Preece MA, Grant DB (1985) Growth curve for girls with Turner syndrome. Arch Dis Child 60:932–935

    Article  CAS  PubMed  Google Scholar 

  17. Massa G, Vanderschueren-Lodeweyckx M, Malvaux P (1990) Linear growth in patients with Turner syndrome: influence of spontaneous puberty and parental height. Eur J Pediatr 149:246–250

    Article  CAS  PubMed  Google Scholar 

  18. Park P, Cohen P (2004) The role of insulin-like growth factor I monitoring in growth hormone-treated children. Horm Res [Suppl 1] 62:59–65

    Google Scholar 

  19. Quigley CA, Crowe BJ, Anglin DG, Chipman JJ (2002) Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab 87:2033–2041

    Article  CAS  PubMed  Google Scholar 

  20. Ranke MB, Dorr HG (2009) Ersatztherapie mit Sexualsteroiden in der Adoleszenz bei Hypogonadismus. Konsensus eines Expertenworkshops. Monatsschr Kinderheilkd 157:260–266

    Article  Google Scholar 

  21. Ranke MB, Grauer ML (1994) Adult height in Turner syndrome: results of a multinational survey 1993. Horm Res 42:90–94

    Article  CAS  PubMed  Google Scholar 

  22. Ranke MB, Saenger P (2001) Turner’s syndrome. Lancet 358:309–314

    Article  CAS  PubMed  Google Scholar 

  23. Ranke MB, Stubbe P, Majewski F, Bierich JR (1988) Spontaneous growth in Turner’s syndrome. Acta Paediatr Scand Suppl 343:22–30

    CAS  PubMed  Google Scholar 

  24. Ranke MB, Lindberg A, Chatelain P et al (2000) Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS International Board. Kabi International Growth Study. J Clin Endocrinol Metab 85:4212–4218

    Article  CAS  PubMed  Google Scholar 

  25. Ranke MB, Partsch CJ, Lindberg A et al (2002) Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: results of the German IGLU follow-up study 2001. Eur J Endocrinol 147:625–633

    Article  CAS  PubMed  Google Scholar 

  26. Ranke MB, Lindberg A, Longas AF et al (2007) Major determinants of height development in Turner syndrome (TS) patients treated with GH: analysis of 987 patients from KIGS. Pediatr Res 61:105–110

    Article  CAS  PubMed  Google Scholar 

  27. Rao E, Weiss B, Fukami M et al (1997) Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 16:54–63

    Article  CAS  PubMed  Google Scholar 

  28. Reiter EO, Blethen SL, Baptista J, Price L (2001) Early initiation of growth hormone treatment allows age-appropriate estrogen use in Turner’s syndrome. J Clin Endocrinol Metab 86:1936–1941

    Article  CAS  PubMed  Google Scholar 

  29. Rochiccioli P, Battin J, Bertrand AM et al (1995) Final height in Turner syndrome patients treated with growth hormone. Horm Res 44:172–176

    Article  CAS  PubMed  Google Scholar 

  30. Rosenfeld RG, Attie KM, Frane J et al (1998) Growth hormone therapy of Turner’s syndrome: beneficial effect on adult height. J Pediatr 132:319–324

    Article  CAS  PubMed  Google Scholar 

  31. Saenger P, Wikland KA, Conway GS et al (2001) Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab 86:3061–3069

    Article  CAS  PubMed  Google Scholar 

  32. Sas TC, Muinck Keizer-Schrama SM de, Stijnen T et al (1999) Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab 84:4607–4612

    Article  CAS  PubMed  Google Scholar 

  33. Savendahl L, Davenport ML (2000) Delayed diagnoses of Turner’s syndrome: proposed guidelines for change. J Pediatr 137:455–459

    Article  CAS  PubMed  Google Scholar 

  34. Schoemaker MJ, Swerdlow AJ, Higgins CD et al (2008) Mortality in women with Turner syndrome in Great Britain: a national cohort study. J Clin Endocrinol Metab 93:4735–4742

    Article  CAS  PubMed  Google Scholar 

  35. Simm D, Degenhardt K, Gerdemann C et al (2008) Chronologisches Alter von Mädchen mit Ullrich-Turner Syndrom bei Diagnosestellung. Klin Padiatr 220:16–20

    Article  CAS  PubMed  Google Scholar 

  36. Soriano-Guillen L, Coste J, Ecosse E et al (2005) Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone. J Clin Endocrinol Metab 90(9):5197–5204

    Article  CAS  PubMed  Google Scholar 

  37. Spiliotis BE (2008) Recombinant human growth hormone in the treatment of Turner syndrome. Ther Clin Risk Manag 4:1177–1183

    CAS  PubMed  Google Scholar 

  38. Stahnke N (2004) Ullrich-Turner-Syndrom und Noonan-Syndrom. Monatsschr Kinderheilkd 152:517–527

    Article  Google Scholar 

  39. Van Pareren YK, Muinck Keizer-Schrama SM de, Stijnen T et al (2002) Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome. J Clin Endocrinol Metab 87:5442–5448

    Article  Google Scholar 

  40. Van Pareren YK, Muinck Keizer-Schrama SM de, Stijnen T et al (2003) Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab 88:1119–1125

    Article  Google Scholar 

Download references

Danksagung

Wir danken der Firma Novo Nordisk GmbH, insbesondere Frau Dr. Pfeifer, Herrn Dr. Schmidt und Herrn Prof. Dr. Knittel, für die Organisation des Workshops.

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung/en hin: Die Autoren und Teilnehmer des Workshops wurden von der Firma Novo Nordisk Pharma GmbH eingeladen, die den Workshop am 25.02.2009 in Frankfurt am Main organisierte. Für Präsentationen einzelner Teilnehmer wurde ein Honorar gezahlt, außerdem wurden die Reisekosten für die Teilnehmer/-innen übernommen.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H.-G. Dörr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dörr, HG., Ranke, M. Therapie mit Wachstumshormon bei Ullrich-Turner-Syndrom. Monatsschr Kinderheilkd 158, 63–70 (2010). https://doi.org/10.1007/s00112-009-2146-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00112-009-2146-z

Schlüsselwörter

Keywords

Navigation